LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Lexicon Pharma (LXRX) Tops Q1 EPS by 6c, Slight Beat on Revenues
April 27, 2020 7:02 AM EDTLexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.63), $0.06 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $7.88 million versus the consensus estimate of $7.79 million.
We achieved 17% growth in XERMELO net sales for the first quarter of 2020 compared to the... More
